Assessing MillerKnoll (MLKN) Valuation After New EIR Healthcare Partnership In Prefabricated Clinics

MillerKnoll (MLKN) is drawing fresh attention after EIR Healthcare agreed to integrate the company’s casework and furniture directly into prefabricated clinic modules, targeting faster, factory-tested healthcare facilities for projects such as Good Samaritan Hospital’s new California clinics. See our latest analysis for MillerKnoll. The EIR Healthcare partnership comes at a time when momentum in MillerKnoll’s share price has softened, with the stock down 16% over the past month and 33.6% over the past 90 days. The 3 year total shareholder return is slightly positive at 2.2%. If this healthcare contract has caught your eye, it could be worth widening your search with a screener focused on healthcare related opportunities such as 32 healthcare AI stocks With MillerKnoll shares down sharply in recent months yet trading at a steep discount to analyst targets and some growth showing in revenue and net income, you have to ask: is this weakness a chance to buy, or is the market already pricing in future growth? Most Popular Narrative: 54.8% Undervalued Analysts who follow MillerKnoll see a fair value of $32 per share, compared with the last close at $14.46, and anchor their view on a detailed long term earnings and margin story. The restructuring of MillerKnoll's reporting segments to better align with strategic goals could improve operational clarity and facilitate growth, potentially boosting revenue and net earnings by optimizing resource allocation and improving market focus. Expansion in the Global Retail segment, including the opening of new stores and the growth of product assortment, could significantly increase future revenue and earnings as it raises brand visibility and captures a larger share of consumer spending. Read the complete narrative. Curious what kind of revenue run rate, margin profile, and future earnings power have to line up to support that $32 mark, and how long that road might be. The underlying narrative spells out specific growth, profitability, and valuation assumptions that go well beyond a simple price target headline. Result: Fair Value of $32 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, tariffs, weaker North America Contract orders, and earlier asset impairments in Retail show that earnings and margin expectations could easily fall short of this upbeat script. Find out about the key risks to this MillerKnoll narrative. Another View: P/E Ratios Flash A Very Different Signal While analysts and our cash flow work point to a fair value of $32 per share, the current P/E of 91.5x tells a very different story. It is far above the US Commercial Services industry at 21.5x, the peer average at 11x, and even the 39x fair ratio, which suggests a lot has to go right to justify today’s earnings multiple. Before you lean too heavily on any single approach, it can help to see what the numbers imply when lined up against peers and that fair ratio benchmark, and then ask yourself which set of assumptions feels more realistic for MillerKnoll over time.See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:MLKN P/E Ratio as at May 2026Next Steps Mixed signals on value and risk so far. If this has you on the fence, take a closer look at the full picture and weigh the 2 key rewards and 4 important warning signs. Looking for more investment ideas? If MillerKnoll has you thinking more broadly about opportunities, do not stop here. Use targeted stock lists to surface ideas you might otherwise miss. Hunt for potential value opportunities by scanning 51 high quality undervalued stocks that pair solid fundamentals with attractive prices. Focus on income by reviewing 13 dividend fortresses that may offer yields above 5% with an emphasis on stability. Prioritize resilience by checking 65 resilient stocks with low risk scores that score well on lower risk metrics. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for Free